Fragile X Syndrome: An Update on Developing Treatment Modalities
- 1 April 2011
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (8), 402-410
- https://doi.org/10.1021/cn200019z
Abstract
Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.Keywords
This publication has 107 references indexed in Scilit:
- 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in ratsBioorganic & Medicinal Chemistry Letters, 2010
- Structure–activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5Bioorganic & Medicinal Chemistry, 2010
- Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndromeBiochemical Pharmacology, 2010
- Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTSBioorganic & Medicinal Chemistry Letters, 2009
- Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5Bioorganic & Medicinal Chemistry Letters, 2009
- Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS studyAmerican Journal of Medical Genetics Part A, 2009
- Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonistsBioorganic & Medicinal Chemistry Letters, 2007
- Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonistsBioorganic & Medicinal Chemistry Letters, 2007
- Reduced Cortical Synaptic Plasticity and GluR1 Expression Associated with Fragile X Mental Retardation Protein DeficiencyMolecular and Cellular Neuroscience, 2002
- Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell, 1991